Observational / CohorttaVNS

Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study

Peña‐Ceballos J, Moloney PB, Munteanu T, Doyle M, Colleran N, Liggan B, Breen A, Murphy S, El‐Naggar H, Widdess‐Walsh P, et al.

Epilepsia · 2023

Key finding

Fifty-seven patients received cenobamate for at least 3 months (median duration, 11 months).

Auto-extracted · verification pendingHow we verify

Condition
Epilepsy
Stimulation
taVNS
Evidence tier
Observational / Cohort
Participants
View on DOI

Share this study

Download the citation card as a PNG, or copy a link to this page.

Cite this study

Peña‐Ceballos, J., Moloney, P. B., Munteanu, T., Doyle, M., Colleran, N., Liggan, B., Breen, A., Murphy, S., El‐Naggar, H., Widdess‐Walsh, P., & Delanty, N. (2023). Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study. Epilepsia, 64(5), 1225-1235. https://doi.org/10.1111/epi.17549

Related studies in Epilepsy

Summary by Vagus Research. Always consult the primary source for the authoritative record.

Stay Current with the Research

Join researchers and practitioners exploring the science of vagus nerve stimulation. Receive curated research summaries and evidence updates.

No spam. Unsubscribe at any time. We respect your privacy.